Ani Arakelian

1.4k total citations
30 papers, 1.1k citations indexed

About

Ani Arakelian is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Ani Arakelian has authored 30 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 16 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Ani Arakelian's work include Epigenetics and DNA Methylation (13 papers), Cancer-related gene regulation (10 papers) and RNA modifications and cancer (8 papers). Ani Arakelian is often cited by papers focused on Epigenetics and DNA Methylation (13 papers), Cancer-related gene regulation (10 papers) and RNA modifications and cancer (8 papers). Ani Arakelian collaborates with scholars based in Canada, United States and Israel. Ani Arakelian's co-authors include Shafaat A. Rabbani, Moshe Szyf, David Cheishvili, Andrew P. Mazar, Niaz Mahmood, Suhad Ali, Haseeb Ahmed Khan, Imrana Tanvir, Gaoping Chen and David E. Shaw and has published in prestigious journals such as Cancer Research, Oncogene and Clinical Cancer Research.

In The Last Decade

Ani Arakelian

29 papers receiving 1.1k citations

Peers

Ani Arakelian

ONCOL

PRM

Gaynor Davies United Kingdom

Sujatha Jagadeeswaran United States

Steven Pirie‐Shepherd United States

María D. Corte‐Torres Spain

Kanji Hojo Japan

Otto Sanchez-Sweatman Canada

Steven A. Enkemann United States

Maryline Allégra France

Katsumi Koshikawa Japan

Paola Franco Italy

Gaynor Davies United Kingdom

Ani Arakelian

576 ×0.8

351 ×1.0

ONCOL

255 ×0.8

99 ×0.6

PRM

141 ×1.0

Citations per year, relative to Ani Arakelian Ani Arakelian (= 1×) peers Gaynor Davies

Countries citing papers authored by Ani Arakelian

Since Specialization

Citations

This map shows the geographic impact of Ani Arakelian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ani Arakelian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ani Arakelian more than expected).

Fields of papers citing papers by Ani Arakelian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ani Arakelian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ani Arakelian. The network helps show where Ani Arakelian may publish in the future.

Co-authorship network of co-authors of Ani Arakelian

This figure shows the co-authorship network connecting the top 25 collaborators of Ani Arakelian. A scholar is included among the top collaborators of Ani Arakelian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ani Arakelian. Ani Arakelian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mahmood, Niaz, Ani Arakelian, Moshe Szyf, & Shafaat A. Rabbani. (2024). Methyl-CpG binding domain protein 2 (Mbd2) drives breast cancer progression through the modulation of epithelial-to-mesenchymal transition. Experimental & Molecular Medicine. 56(4). 959–974. 7 indexed citations

Arakelian, Ani, et al.. (2023). S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas. Neoplasia. 36. 100874–100874. 7 indexed citations

Arakelian, Ani, et al.. (2022). Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone. Cancers. 15(1). 48–48. 8 indexed citations

Mahmood, Niaz, Ani Arakelian, Haseeb Ahmed Khan, et al.. (2020). uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions. Bone Research. 8(1). 18–18. 25 indexed citations

Cheishvili, David, et al.. (2020). DNA methylation signatures of Prostate Cancer in peripheral T-cells. BMC Cancer. 20(1). 588–588. 31 indexed citations

Mahmood, Niaz, Ani Arakelian, Catalin Mihalcioiu, et al.. (2020). Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma. Frontiers in Oncology. 10. 16 indexed citations

Mahmood, Niaz, Ani Arakelian, William J. Muller, Moshe Szyf, & Shafaat A. Rabbani. (2020). An enhanced chemopreventive effect of methyl donor S-adenosylmethionine in combination with 25-hydroxyvitamin D in blocking mammary tumor growth and metastasis. Bone Research. 8(1). 15 indexed citations

Cheishvili, David, Niaz Mahmood, Ani Arakelian, et al.. (2018). DNA methylation signatures of breast cancer in peripheral T-cells. BMC Cancer. 18(1). 574–574. 35 indexed citations

Cheishvili, David, Niaz Mahmood, Ani Arakelian, et al.. (2018). Identification of an Epigenetic Signature of Osteoporosis in Blood DNA of Postmenopausal Women. Journal of Bone and Mineral Research. 33(11). 1980–1989. 45 indexed citations

10.

Mahmood, Niaz, David Cheishvili, Ani Arakelian, et al.. (2017). Methyl donor S-adenosylmethionine (SAM) supplementation attenuates breast cancer growth, invasion, and metastasisin vivo; therapeutic and chemopreventive applications. Oncotarget. 9(4). 5169–5183. 50 indexed citations

11.

Cheishvili, David, Ani Arakelian, Zahid Hussain, et al.. (2015). S‐adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: therapeutic and diagnostic clinical applications. Cancer Medicine. 4(5). 732–744. 51 indexed citations

12.

Stefañska, Barbara, David Cheishvili, Matthew Suderman, et al.. (2014). Genome-Wide Study of Hypomethylated and Induced Genes in Patients with Liver Cancer Unravels Novel Anticancer Targets. Clinical Cancer Research. 20(12). 3118–3132. 91 indexed citations

13.

Cheishvili, David, Matthew Suderman, Ani Arakelian, et al.. (2014). Synergistic effects of combined DNA methyltransferase inhibition and MBD2 depletion on breast cancer cells; MBD2 depletion blocks 5-aza-2ʹ-deoxycytidine-triggered invasiveness. Carcinogenesis. 35(11). 2436–2446. 17 indexed citations

14.

Rabbani, Shafaat A., Ani Arakelian, & Riaz Farookhi. (2013). LRP5 knockdown: effect on prostate cancer invasion growth and skeletal metastasis in vitro and in vivo. Cancer Medicine. 2(5). 625–635. 36 indexed citations

15.

Harfouche, Rania, et al.. (2010). Estradiol-dependent regulation of angiopoietin expression in breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 123(1-2). 17–24. 11 indexed citations

16.

Rabbani, Shafaat A., Bushra Ateeq, Ani Arakelian, et al.. (2010). An Anti-Urokinase Plasminogen Activator Receptor Antibody (ATN-658) Blocks Prostate Cancer Invasion, Migration, Growth, and Experimental Skeletal Metastasis In Vitro and In Vivo. Neoplasia. 12(10). 778–788. 70 indexed citations

17.

Rabbani, Shafaat A., et al.. (2005). Regulation of Parathyroid Hormone-Related Peptide by Estradiol: Effect on Tumor Growth and Metastasis in Vitro and in Vivo. Endocrinology. 146(7). 2885–2894. 22 indexed citations

18.

Arakelian, Ani, et al.. (2005). Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer. Oncogene. 24(44). 6657–6666. 22 indexed citations

19.

Arakelian, Ani, et al.. (2003). [Circulating immune complexes in ischemic and hemorrhagic strokes].. PubMed. 44–7.

20.

Shukeir, Nicholas, Ani Arakelian, Salam Kadhim, Seema V. Garde, & Shafaat A. Rabbani. (2003). Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer.. PubMed. 63(9). 2072–8. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact